To include your compound in the COVID-19 Resource Center, submit it here.

Radius rises on Phase I breast cancer readout

Radius Health Inc. (NASDAQ:RDUS) gained $4.19 (15%) to $31.60 after reporting data from the Phase I 005 trial of elacestrant (RAD1901) in heavily pretreated, estrogen receptor-positive, HER2-negative patients with advanced breast cancer. Early next year,

Read the full 351 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE